Call for Papers

Special Issue on “Pharmacogenetics of Cancer”

Guest Editors:

      Prof. Enrico Mini, MD, PhD
      Department of Health Sciences, University of Florence, Florence, Italy.
      Email :
      Dr. Stefania Nobili, PharmD, PhD
      Department of Health Sciences, University of Florence, Florence, Italy.
      Email :


Cancer Drug Resistance will publish in 2018 a special issue on “Pharmacogenetics of Cancer”. This issue, which is planned for the second half of the year, will be guest edited by
Prof. Enrico Mini (Department of Experimental and Clinical Medicine, University of Florence, Italy), and Dr. Stefania Nobili (Department of Health Sciences, University of Florence, Italy).
Pharmacogenetics and pharmacogenomics has expanded rapidly over the past years and is the basis of personalized medicine. The pharmacological treatment of cancer is an ideal field for the application of pharmacogenetics into clinical practice. Testing of patients for genetic markers of efficacy or toxicity of anticancer therapy is increasingly being used as a result of clinical studies based on genotype stratification, availability of approved clinical tests and of an always more robust clinical pharmacogenetic information and guidelines.
This special issue of Cancer Drug Resistance is designed to provide an overview of the role of pharmacogenetics and pharmacogenomics in cancer treatment, including methods of discovery and clinical drug development, available information on drug labels and web resources, guidelines, with particular regard to specific cancer drug classes. Finally, the integration of somatic pharmacogenomic markers into clinical practice with examples of main cancer types will be also addressed.

Why submit to us:

• Rigorous mechanism in peer review: one manuscript must be reviewed by at least two relevant experts. We will endeavour to ensure high standards for the review process and subsequent publication by a team of efficient and professional reviewers and scientific editors.
• No publication fee: there would be absolutely no charge for publication.
• Rapid publication: we will do our best to ensure that accepted papers will be published rapidly with a high quality.
• Open Access: As an author you will retain the copyright to your work. By licensing your work under the Creative Commons Attribution 4.0 License, articles can be re-used and re-distributed without restriction, as long as the original work is correctly cited.
• Wide promotions: Published articles will be promoted at academic conferences, through social networks for scientists and relevant indexing services.

Deadline for Submissions:

31 October 2018


Please click here for Author Instructions.
Please click here to submit your paper.

For administrative support and general queries, please contact:
Elaine Gao, Managing Editor,
Mary Ma, Editor,

Cancer Drug Resistance ISSN 2578-532X (Online)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.